Details of the Drug
General Information of Drug (ID: DM7BQ65)
| Drug Name |
4-Hydroxy-2-Butanone
|
||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms |
4-Hydroxy-2-butanone; 4-Hydroxybutan-2-one; 590-90-9; 2-Butanone, 4-hydroxy-; Methylolacetone; 3-Oxo-1-butanol; 3-Oxobutanol; 3-Ketobutan-1-ol; Monomethylolacetone; 4-Butanol-2-one; UNII-TCM0BJ44MF; 2-Hydroxyethyl methyl ketone; NSC 41219; TCM0BJ44MF; CH3C(O)CH2CH2OH; LVSQXDHWDCMMRJ-UHFFFAOYSA-N; BUQ; Ketones, C4-6, beta-hydroxy; 3-ketobutanol; 4-hydroxy butanone; EINECS 209-693-6; 1-hydroxy-3-butanone; 4-oxidanylbutan-2-one; 1d7j; 1 -hydroxy-3-butanone; 4-hydroxy-butan-2-one; AI3-11747; EC 209-693-6; ACMC-1B12A
|
||||||||||||||||||||||
| Indication |
|
||||||||||||||||||||||
| Drug Type |
Small molecular drug
|
||||||||||||||||||||||
| Structure |
![]() |
||||||||||||||||||||||
| 3D MOL | 2D MOL | ||||||||||||||||||||||
| #Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 88.11 | |||||||||||||||||||||
| Logarithm of the Partition Coefficient (xlogp) | -0.8 | ||||||||||||||||||||||
| Rotatable Bond Count (rotbonds) | 2 | ||||||||||||||||||||||
| Hydrogen Bond Donor Count (hbonddonor) | 1 | ||||||||||||||||||||||
| Hydrogen Bond Acceptor Count (hbondacc) | 2 | ||||||||||||||||||||||
| Chemical Identifiers |
|
||||||||||||||||||||||
| Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
| The Studied Disease | Discovery agent | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
| Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||


